Back to top
more

Kite Pharma, Inc. (KITE)

(Delayed Data from NSDQ)

$179.79 USD

179.79
3,761,989

-0.02 (-0.01%)

Updated Oct 2, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Arpita Dutt headshot

5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote

It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.

    Novartis CAR-T Therapy Drug Recommended by FDA Panel

    Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).

      Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

      Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

        Pfizer's (PFE) Leukemia Candidate Receives Approval in EU

        Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.

          Eric Dutram headshot

          How Kite Pharma Is Revolutionizing the Fight Against Cancer

          Immunotherapy is a hot corner of the biotech world. Learn how companies in this sector fight cancer in this podcast which features Dr. David Chang, the Chief Medical Officer of Kite Pharma. Do not miss it!

            Arpita Dutt headshot

            M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

            The biotech sector's fundamentals remain strong.

              Sweta Killa headshot

              ETF Winner of 1H17 and its Top 5 Stocks

              Inside the top performing ETF of the first half of 2017.

                Why Is Kite Pharma (KITE) Up 6.3% Since the Last Earnings Report?

                Kite Pharma (KITE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?

                  Shares of Kite Pharma, Inc. (KITE) were up around 5.6% on Thursday.

                    Kite Pharma (KITE) Releases Data on Lead Drug for Leukemia

                    Kite Pharma, Inc. (KITE) announced results from phase I trial, ZUMA-3, on lead candidateKTE-C19 (axicabtagene ciloleucel) in adults with high burden relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

                      Kite Pharma Cancer Drug BLA Gets Priority Review Status

                      Kite Pharma, Inc. (KITE) announced that its biologics license application (BLA) for its experimental CAR-T therapy, axicabtagene ciloleucel has been accepted for priority review by the FDA.

                        Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death

                        Kite Pharma, Inc. (KITE) reported wider-than-expected loss in the first quarter of 2017.

                          Ryan McQueeney headshot

                          Here's Why Kite Pharma (KITE) Stock Is Plummeting Today

                          Shares of Kite Pharma (KITE) slipped more than 13% in morning trading Monday after it was revealed that a cancer patient died from brain swelling following treatment with the company's CAR-T therapy KTE-C19.

                            Kite Pharma (KITE) Q1 Loss Wider than Expected, Sales Miss

                            KITE reported first-quarter 2017 loss of 1.74 cents per share, wider than our consensus estimate of a loss of $1.68 cents per share.

                              Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?

                              Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens.

                                Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status

                                Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.

                                  Kite Pharma Completes Filing for CAR-T Therapy with FDA

                                  Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.

                                    Novartis' CTL109 BLA Gets Priority Review Status from FDA

                                    Novartis A.G. (NVS) announced that the FDA has accepted and granted priority review designation to its biologics license application (BLA) for pipeline candidate, CTL019 (tisagenlecleucel-T).

                                      Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval

                                      Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.

                                        Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data

                                        Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.

                                          Kite Pharma (KITE) Q4 Loss Narrower than Expected

                                          KITE reported fourth quarter 2016 loss of 1.70 cents per share, narrower than our consensus estimate of a loss of $1.75 cents per share.

                                            Allergan (AGN) Q4 Earnings: What's in Store for the Stock?

                                            Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.

                                              GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

                                              GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

                                                Arpita Dutt headshot

                                                Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?

                                                The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.

                                                  Biogen (BIIB) Presents Positive Phase III Data on Spinraza

                                                  Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).